Sales · healthcare · APACJul 20269 min read365 words

Modern cold calling for startups under 20 people for healthcare and life sciences in the APAC region

How under-20-person startups get modern cold calling live without hiring — the specific version of the playbook designed for constraint. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the APAC region.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install modern cold calling has to be shaped to that reality from day one.

The under-20-person version of modern cold calling is not a diluted enterprise playbook. It is using the phone as a precision tool, not a volume weapon with different constraints: no headcount, no politics, and no time to be wrong for long.

Own it personally as a founder or lean-in operator for the first quarter. Hiring a specialist too early replaces context with process.

Pick one channel, one trigger, one message. Two of anything at this stage is too many and none of them will work.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Modern cold calling is only useful here when it is pointed at both constraints at once.

Instrument connects per hour on ICP dials in a spreadsheet if you have to. Legibility beats sophistication under 20 people.

The startup-specific trap is power dialers that torch the list in a week, usually because a well-meaning advisor points at what worked at their $50m company. Ignore.

Budget rules: whatever you spend on tools, spend the same on the person operating them. Under-tooling is fine; under-humaning is not.

A working modern cold calling function at 15 people is a genuine moat — most competitors of that size do not have one, and the discipline carries forward as the company grows.

Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing modern cold calling deliberately for this market rather than importing a playbook designed for somewhere else.

cold callingoutbound callingphone prospectingstartup cold callingcold calling for early stagecold calling for healthcare and life sciencescold calling in the APAC regionhealthcare and life sciences growth in the APAC region

Frequently asked questions

Sales · healthcare · APAC — answered

Does modern cold calling work for healthcare and life sciences in the APAC region?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market. The healthcare teams that install this get past procurement instead of dying in it.
Can a five-person team run modern cold calling?
Yes, if the founder owns it. The lower headcount, the more concentrated the ownership.
What is the smallest useful modern cold calling setup?
One channel, one trigger, one message, and a spreadsheet tracking connects per hour on ICP dials.
Should we hire a specialist for modern cold calling?
Not in the first quarter. Own it personally until the model is proven.
What common advice should startups ignore?
Anything derived from a company more than 10x larger. Constraints differ.
What is the APAC-specific pitfall when running modern cold calling for healthcare?
Importing a playbook that was built for another market. In the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market — the install has to reflect that.

Growth Broker editorial

Filed under sales · healthcare · apac

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call